President Trump will sign an executive order on Monday that is aimed at reducing some drug prices in the United States by aligning them with what other rich countries pay, he said about truth social On Sunday evening.
The proposal that he described that just cannot shift is what he calls a “most favorite nation” price model. Mr. Trump has not provided any details about which type of insurance the plan would apply or how many medicines it would focus on, but he indicated that the United States would have to pay the lowest price under his peer countries.
“Our country will finally be treated fairly, and our health care costs of the citizens will be reduced by figures that has never thought before,” he wrote in his social media post.
Such a plan will most likely be subject to challenges before the court, and it is not clear whether it will pass the legal collection, especially without action by the congress.
In his first term, Mr. Trump tried to perform in vain A version of this idea For Medicare, the health insurance program that covers itself 68 million Americans who are older than 65 or have a disability. That plan would only apply to 50 medicines, administered in clinics and hospitals, which are paid by Medicare. A federal court blocked it and ruled that the government had done Steps skipped In the policy process.
The pharmaceutical industry opposes the idea that it would almost certainly be cut in its winnings, and has babbled against it because the discussions about the policy have been recovered in Washington in recent weeks. Companies have warned that such a policy would cause them to spend less on research and to deprive patients with new medicines.
“Price environment of the government in any form is bad for US patients,” said Alex Schriver, an officer at the most important lobbying group of the drug industry, Phrma, in a statement. He added: “Policy makers must concentrate on repairing the errors in the American system, not importing failed policy from abroad.”
Mr Trump’s embrace of the idea distinguishes him from most Republicans, who are often skeptical towards the government prize. Democratic legislators have presented versions of the idea.
Ameet Sarpatwari, an expert in pharmaceutical policy at the Harvard Medical School, said that Mr. Trump used an idea that ‘populist profession’ had.
Mr. Trump has a long time complained That the United States pay much more than other rich countries for the same medicines. And he’s right. In the United States there are prices for brand medicines Three times as highOn average, like that in Peer countries.
That is despite the fact that much of the research that leads to new drugs takes place in American laboratories and hospitals.
Drug makers generate one substantial majority From their worldwide profit of sales in the United States and usually design their business strategy around the American market.
Pharmaceutical companies claim that the higher prices in the United States have an additional advantage: industrial analyzes have shown that patients in the United States receive medication fasterAnd with fewer insurance restrictions than those in other countries.
- Advertisement -
